WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 47.50
-1.34 (-2.74%)
Sep 10, 2026, 4:08 PM HKT
WuXi Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 23,624 | 21,790 | 18,675 | 17,034 | 15,269 | 10,290 | |
Revenue Growth | 17.80% | 16.68% | 9.63% | 11.56% | 48.38% | 83.34% |
Cost of Revenue | 12,410 | 11,772 | 11,025 | 10,206 | 8,545 | 5,461 |
Gross Profit | 11,214 | 10,019 | 7,651 | 6,828 | 6,724 | 4,829 |
Selling, General & Admin | 2,445 | 2,313 | 2,147 | 1,789 | 1,433 | 1,001 |
Research & Development | 940.08 | 853.37 | 766.44 | 785.82 | 682.82 | 501.58 |
Other Operating Expenses | - | - | - | 23.47 | -1.49 | 24.29 |
Operating Expenses | 3,564 | 3,372 | 3,065 | 2,895 | 2,374 | 1,659 |
Operating Income | 7,650 | 6,646 | 4,585 | 3,933 | 4,350 | 3,170 |
Interest Expense | -102.87 | -143.06 | -157.59 | -158.49 | -64.38 | -39.19 |
Interest & Investment Income | 443.33 | 434.65 | 351.54 | 219.18 | 115.79 | 58.03 |
Currency Exchange Gain (Loss) | -870.01 | -267.45 | -45.22 | 46.73 | 417.2 | -32.58 |
Other Non Operating Income (Expenses) | 150.35 | 175.46 | 191.45 | 173.38 | 159.56 | 171.36 |
EBT Excluding Unusual Items | 7,271 | 6,846 | 4,926 | 4,214 | 4,978 | 3,328 |
Gain (Loss) on Sale of Investments | 444.48 | 1,045 | -91.72 | 13.83 | 379.44 | 665.44 |
Gain (Loss) on Sale of Assets | -367.57 | -634.68 | 0.46 | - | - | - |
Other Unusual Items | - | - | - | -53.58 | - | - |
Pretax Income | 7,348 | 7,257 | 4,834 | 4,174 | 5,358 | 3,993 |
Income Tax Expense | 1,455 | 1,524 | 889.03 | 603.18 | 807.87 | 484.54 |
Earnings From Continuing Operations | 5,893 | 5,733 | 3,945 | 3,571 | 4,550 | 3,509 |
Minority Interest in Earnings | -883.94 | -824.88 | -589.29 | -170.9 | -129.62 | -120.1 |
Net Income | 5,009 | 4,908 | 3,356 | 3,400 | 4,420 | 3,388 |
Net Income to Common | 5,009 | 4,908 | 3,356 | 3,400 | 4,420 | 3,388 |
Net Income Growth | 19.36% | 46.25% | -1.28% | -23.09% | 30.45% | 100.63% |
Shares Outstanding (Basic) | 4,063 | 4,027 | 4,082 | 4,164 | 4,173 | 4,174 |
Shares Outstanding (Diluted) | 4,173 | 4,176 | 4,227 | 4,349 | 4,376 | 4,422 |
Shares Change | -0.45% | -1.22% | -2.80% | -0.62% | -1.04% | 5.05% |
EPS (Basic) | 1.23 | 1.22 | 0.82 | 0.82 | 1.06 | 0.81 |
EPS (Diluted) | 1.18 | 1.16 | 0.78 | 0.77 | 1.01 | 0.77 |
EPS Growth | 19.83% | 47.93% | 1.55% | -23.50% | 31.17% | 92.50% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 2,656 | 1,288 | 622.14 | -326.72 | -3,077 |
Free Cash Flow Per Share | - | 0.64 | 0.30 | 0.14 | -0.07 | -0.70 |
Gross Margin | 47.47% | 45.98% | 40.97% | 40.08% | 44.04% | 46.93% |
Operating Margin | 32.38% | 30.50% | 24.55% | 23.09% | 28.49% | 30.81% |
Profit Margin | 21.20% | 22.53% | 17.97% | 19.96% | 28.95% | 32.93% |
Free Cash Flow Margin | - | 12.19% | 6.89% | 3.65% | -2.14% | -29.90% |
EBITDA | 8,843 | 7,925 | 5,849 | 4,928 | 5,069 | 3,622 |
EBITDA Margin | 37.43% | 36.37% | 31.32% | 28.93% | 33.20% | 35.20% |
D&A For EBITDA | 1,192 | 1,278 | 1,263 | 995.46 | 718.63 | 452.24 |
EBIT | 7,650 | 6,646 | 4,585 | 3,933 | 4,350 | 3,170 |
EBIT Margin | 32.38% | 30.50% | 24.55% | 23.09% | 28.49% | 30.81% |
Effective Tax Rate | 19.80% | 21.00% | 18.39% | 14.45% | 15.08% | 12.13% |